P-287Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study

ABSTRACT:

SUBMITTER: Andrew D 

PROVIDER: S-EPMC4984074 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature